FranceFrance

Sanofi's MS-drug Alemtuzumab meets first primary goal

12.07.2011

French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to Rebif. The CARE-MS I study incorporated 581 patients with relapsing-remitting multiple sclerosis who had not had prior treatment for their illness and showed that Lemtrada helped patients more than Rebif, Merck KGaA's established multiple sclerosis therapy. The product cut relapse rates by 55 percent over two years compared with Rebif Sanofi said in a statement on Monday. But Lemtrada failed on the second goal; statistically, it is not better than Rebif in helping stave off disability for the duration of the test. Sanofi's shares not unexpectedly fell after the announcement. Another Phase 3 clinical trial, CARE-MS II, is currently underway, evaluating Lemtrada against Rebif in relapsing-remitting multiple sclerosis patients who have relapsed while on therapy. The medicine’s prospects were at the heart of the Genzyme takeover talks this year. Cambridge, Massachusetts-based Genzyme was projecting peak annual sales of as much as $3.5 billion, saying Lemtrada was likely to become its bestseller. Sanofi said in October that analysts’ estimates of about $700 million were a valuation “probably closer to the reality of the product.” Sanofi expects to file the drug for U.S. and European Union approval in multiple sclerosis in early 2012 and has been granted fast track designation by the U.S. FDA. Sanofi has time. Cash is not the problem. On Monday the French drugmaker revealed it was selling its Dermik dermatology business to Canada's Valeant Pharmaceuticals for $425 million.

Tech Review

01.02.2010

The market share of ultrafast sequencing machines on the total sequencing market is set to expand rapidly. In April 2010, Roche daughter 454 Life Sciences (Branford, US) is launching a new system especially designed for...

Tech Review

01.02.2010

Luxembourg has appeared from nowhere with an initiative to set up a European center for diagnostic biomarkers, while it’s government has set aside EUR140m to reach some ambitious goals. To speed up development, Luxembourg looked...

Tech Review

01.02.2010

Systems biology is aimed at achieving a holistic understanding of living organisms, while synthetic biology seeks to design and construct new living organisms with targeted functionalities. Genome sequencing and the fields of...

Politics / Law

01.02.2010

Europe is to receive a new Super Commissioner for biotech, as well as the largest budget for research the bloc has ever granted. Even before the start of hearings considering the 26 Commission nominees that began in mid-January,...

Editorial

01.02.2010

The new EU Commissioner-Delegate for Health and Consumer Policy made his case to the European Parliament in January, and has now been granted a revamped portfolio of previously distinct health-related organisations and...

BioFunding

26.01.2010

Reykjavik – Iceland's deCode Genetics has reimmerged as a private biotechnology company following its purchase from its former parent company by Saga Investments LLC, a consortium that includes Polaris Ventures and ARCH Venture...

Politics / Law

31.12.2009

Darmstadt/Berlin – Cultivation of GM maize in the EU fell sharply in 2009, according to figures from transgen.de. The most active country is still Spain, which makes up more than 80% of all GM cultivation. In 2009, European...

Politics / Law, GermanyGermany

30.12.2009

Germany has launched Europe’s first civil high-throughput screening facility for high-risk infectious agents within the framework of ERA-NET PathoGenoMics. The novel bio-safety level 3 (BSL3) unit at the Max Planck Institute for...

Politics / Law

28.12.2009

Brussels/Strasbourg – John Dalli, the designated Super Commissioner for Biotechnology has set out his future priorities as Health Commissioner of the European Commission. In a document published on 23 December by the European...

Displaying results 351 to 360 out of 1983

< Previous 351-360 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/35/article/sanofis-ms-drug-alemtuzumab-meets-first-primary-goal.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%
  • ADDEX3.30 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 24.10.2014


Current issue

All issues

Product of the week

Products